Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myeloproliferative Disorders 7Primary Myelofibrosis 4Thrombocythemia, Essential 1Polycythemia Vera 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Neutrophilic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia 1Hematologic Neoplasms 1Blast Crisis 1

Interventions

Cyclophosphamide 125fludarabine phosphate 116Busulfan 98Peripheral Blood Stem Cell Transplantation 88Filgrastim 73Antilymphocyte Serum 72Tacrolimus 67Cytarabine 67Cyclosporine 64Mycophenolic Acid 63Methotrexate 57Radiotherapy 54fludarabine 52Whole-Body Irradiation 52Melphalan 49Imatinib Mesylate 41Azacitidine 35Methylprednisolone 34Etoposide 33Cord Blood Stem Cell Transplantation 30Granulocyte Colony-Stimulating Factor 28sargramostim 26Thiotepa 26Decitabine 21Alemtuzumab 21Clofarabine 20thymoglobulin 19Stem Cell Transplantation 19nilotinib 18Interferon-alpha 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia × fedratinib × Myeloid × Clear all
NCT04955938 2024-07-31

A Study of Fedratinib With IDH Inhibition in Advanced-Phase, IDH-Mutated Ph-Negative Myeloproliferative Neoplasms

University of Chicago

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡